Genpharmasec Ltd
Genpharmasec Ltd (GENPHARMA) last reported results for the quarter ended Jun 2026, with sales of ₹49.71 crore and net profit of ₹-0.17 crore. The stock last traded at ₹1.1, a market capitalisation of ₹60.9 crore. Over the past 52 weeks the stock has ranged between ₹0.75 and ₹1.9. Figures are as of 6 Oct 2026 and are not real time.
Genpharmasec Ltd share price and key metrics
- Current price
- ₹1.1
- Market cap
- ₹60.9 cr
- Book value
- ₹1.2
- ROE
- 2.36%
- ROCE
- 2.68%
- Dividend yield
- 0.00%
- 52w high / low
- 1.90/0.75
Metrics as of 6 Oct 2026. Not real time.
Track Genpharmasec Ltd
Cruxal reads every Genpharmasec Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Genpharmasec Ltd growth and returns
- 10 Years
- %
- 5 Years
- %
- 3 Years
- 76%
- TTM
- 338%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- 11%
- TTM
- -111%
- 10 Years
- 21%
- 5 Years
- -25%
- 3 Years
- -22%
- 1 Year
- -41%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- 2%
- Last Year
- 2%
Genpharmasec Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹49.71 cr, up 312.9% from ₹12.04 cr a year earlier. Net profit swung to a loss of ₹0.17 cr.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 6.03 | 8.48 | 14.01 | 12.04 | 32.64 | 39.83 | 55.43 | 49.71 |
| Expenses | 5.9 | 7.76 | 15.01 | 11.1 | 33.1 | 41.07 | 53.44 | 48.75 |
| Operating profit | 0.13 | 0.72 | -1 | 0.94 | -0.46 | -1.24 | 1.99 | 0.96 |
| OPM % | 2.16% | 8.49% | -7.14% | 7.81% | -1.41% | -3.11% | 3.59% | 1.93% |
| Other income | 0.75 | 0.81 | 0.94 | 0.69 | 0.46 | 0.98 | 1.02 | 0.37 |
| Interest | 0.07 | 0.16 | 0.11 | 0.12 | 0.23 | 0.41 | 0.48 | 0.4 |
| Depreciation | 0.3 | 0.1 | 0.26 | 0.27 | 0.56 | 0.67 | 0.68 | 0.67 |
| Profit before tax | 0.51 | 1.27 | -0.43 | 1.24 | -0.79 | -1.34 | 1.85 | 0.26 |
| Tax % | -39.22% | 40.16% | -37.21% | 2.42% | 48.10% | -37.31% | 27.03% | 165.38% |
| Net profit | 0.7 | 0.76 | -0.27 | 1.22 | -1.18 | -0.83 | 1.36 | -0.17 |
| EPS (₹) | 0.01 | 0.01 | -0.00 | 0.02 | -0.02 | -0.01 | 0.03 | 0.00 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Genpharmasec Ltd annual results
| ₹ crore | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|
| Sales | 26 | 30 | 34 | 140 | 178 |
| Operating profit | 0 | 0 | 0 | 1 | 1 |
| OPM % | 1.0% | 0.1% | 1.2% | 0.9% | 0.7% |
| Net profit | 1 | -0 | 2 | 1 | -1 |
| EPS (₹) | 0.02 | -0.00 | 0.03 | 0.03 | -0.00 |
TTM is the trailing twelve months to the most recent quarter.
Genpharmasec Ltd balance sheet
| ₹ crore | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Equity capital | 28 | 55 | 55 | 55 |
| Reserves | -12 | 9 | 10 | 11 |
| Borrowings | 3 | 4 | 5 | 35 |
| Other liabilities | 1 | 3 | 9 | 37 |
| Total liabilities | 20 | 71 | 80 | 138 |
| Fixed assets | 0 | 1 | 8 | 41 |
| CWIP | 0 | 0 | 0 | 0 |
| Investments | 1 | 19 | 20 | 2 |
| Other assets | 19 | 51 | 53 | 95 |
| Total assets | 20 | 71 | 80 | 138 |
As reported by the company. Total assets equal total liabilities by construction.
Genpharmasec Ltd cash flow
| ₹ crore | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Cash from operations | -3 | -3 | 3 | -18 |
| Cash from investing | 0 | -28 | -4 | 13 |
| Cash from financing | 3 | 48 | -1 | 4 |
| Net cash flow | 0 | 17 | -3 | -0 |
| Free cash flow | -3 | -3 | -3 | -18 |
| CFO / operating profit | -1,277% | -7,275% | 774% | -1,274% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Genpharmasec Ltd operating ratios
| Per year | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| ROCE % | — | 2% | 4% | 3% |
| Debtor days | 82 | 109 | 147 | 76 |
| Inventory days | 151 | 133 | 89 | 40 |
| Days payable | 21 | 36 | 101 | 91 |
| Cash conversion cycle | 211 | 207 | 135 | 26 |
| Working capital days | 199 | 213 | 123 | 61 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Genpharmasec Ltd shareholding pattern
Promoters held 29.98% at Jun 2026, broadly unchanged since Jun 2025.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 29.98% | 29.98% | 29.98% | 29.98% | 29.98% | 29.98% | 29.98% | 29.98% |
| Public | 70.02% | 70.02% | 70.02% | 70.02% | 70.03% | 70.01% | 70.02% | 70.02% |
| No. of shareholders | 1,05,838 | 1,09,206 | 1,09,080 | 1,07,602 | 1,05,804 | 1,04,021 | 1,02,252 | 1,01,134 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Genpharmasec Ltd corporate filings
- Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026.Company Updatelow impact
- Genpharmasec Limited's Voting Results Reveal Requisite Majorities for Multiple Resolutions at 34th AGMAGM/EGMhigh impact
Cruxal's analysis: Genpharmasec Limited held its 34th AGM on 29 September 2026 via VC/OAVM. The voting…
Read the full analysis - Submission of Proceeding of the 34th Annual General Meeting of the Member of the Genpharmasec Ltd held on Tuesday, 29th September, 2026.AGM/EGMmedium impact
- Intimation of Closure of Trading window.Insider Trading / SASTlow impact
- Genpharmasec Limited Announces 34th Annual General Meeting Scheduled for September 29, 2026Company Updatelow impact
Cruxal's analysis: Genpharmasec Limited has issued a formal notice for its 34th Annual General Meeting (AGM)…
Read the full analysis - Genpharmasec Ltd releases Annual Report for Financial Year 2025-26Otherslow impact
Cruxal's analysis: Genpharmasec Ltd has filed its Annual Report for the financial year 2025-26. The…
Read the full analysis - Genpharmasec Limited Announces 34th AGM and Seeks Approval for Managerial Re-appointment and Inter-Corporate LoansAGM/EGMlow impact
Cruxal's analysis: Genpharmasec Limited has issued a notice for its 34th Annual General Meeting scheduled…
Read the full analysis - Genpharmasec Limited announces book closure dates for 34th Annual General MeetingCorp. Actionlow impact
Cruxal's analysis: Genpharmasec Limited has formally notified the BSE regarding the closure of its Register…
Read the full analysis - Genpharmasec Limited Announces 34th AGM and Re-appointment of Whole Time DirectorBoard Meetinglow impact
Cruxal's analysis: Genpharmasec Limited has scheduled its 34th Annual General Meeting for September 29…
Read the full analysis - Promoter Rajesh Mirchumal Sadhwani Increases Stake in Genpharmasec Limited via Open Market PurchaseInsider Trading / SASTmedium impact
Cruxal's analysis: Genpharmasec Limited promoter Rajesh Mirchumal Sadhwani has increased his shareholding by…
Read the full analysis - Genpharmasec Limited Promoter Increases Stake to 30.88% via Open Market AcquisitionInsider Trading / SASTmedium impact
Cruxal's analysis: Genpharmasec Limited promoter, Rajesh Mirchumal Sadhwani, has increased his shareholding…
Read the full analysis - Genpharmasec Limited schedules Board Meeting for 02 September 2026 to finalize 34th Annual General Meeting logisticsBoard Meetinglow impact
Cruxal's analysis: Genpharmasec Limited has issued a formal intimation regarding a Board of Directors…
Read the full analysis - Genpharmasec Ltd enters into a business agreement with Amneal Healthcare Private LimitedCompany Updatemedium impact
Cruxal's analysis: Genpharmasec Ltd has announced a formal agreement with Amneal Healthcare Private Limited…
Read the full analysis - Genpharmasec Limited reports Q1 FY2027 financial results via newspaper publicationCompany Updatelow impact
Cruxal's analysis: Genpharmasec Limited has published its unaudited standalone and consolidated financial…
Read the full analysis - Genpharmasec Limited confirms nil deviation in utilization of Rights Issue proceeds for quarter ended June 2026Company Updatelow impact
Cruxal's analysis: Genpharmasec Limited has filed a statement confirming that there is no deviation or…
Read the full analysis - Genpharmasec Limited reports Q1 FY2027 consolidated net loss of 0.17 crore amid rising operational costsBoard Meetinghigh impact
Cruxal's analysis: Genpharmasec Limited reported a consolidated net loss of 0.17 crore for the quarter ended…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.